Sustained virological response = (SVR) rates:
• Overall SVR was 63%, which is the highest response rate ever re-ported in
a hepatitis C treatment clinical trial.
• Genotype 1 = 52% SVR.
• Genotype 1, high viral load = 47% SVR.
• Genotype 1, low viral load = 65% SVR.
• Genotypes 2 and 3 = 84% SVR.
• Genotypes 2 and 3, high viral load = 82% SVR.
• Genotypes 2 and 3, low viral load = 88% SVR.
FDA-approved
Combination Therapy
-
Pegasys + Copegus
-
(peginterferon
alfa-2a + ribavirin)
-
PEG-Intron + Rebetol
-
(peginterferon
alfa-2b + ribavirin
-
Intron A + Rebetol
-
(standard
interferon alfa-2b + ribavirin)
-
Roferon A +
Ribavirin
-
(interferon alfa-2a + ribavirin)
Janis and Friends Forum: Read and Comment on
2008 EASL Coverage.
New HCV Drugs Panel Discussion at EASL 2008
Factors Predicting Response to Therapy for
Chronic Hepatitis C
-
COLCHICINE VERSUS
PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT
TRIAL
First Studies Demonstrating Greater than 60%
Sustained Viral Response Rates with Half the Standard Treatment Duration in
Genotype 1 Chronic Hepatitis C Patients (Vertex press release)
Twice vs Once Weekly Dosing of Peginterferon Alfa 2a
in Chronic HCV Genotype 1 Infection: Analysis of Early Viral Kinetics
Oct 07
FDA Safety Changes: Copegus, Intron A
